IP Library Granted Patent US 8,097,655
Granted Patent B2
US 8,097,655 · App. 13/109,034 · Granted Jan 17, 2012

Methods for concomitant administration of colchicine and macrolide antibiotics

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,655
App. No.
13/109,034
Granted
Jan 17, 2012
Kind
B2
Abstract

Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.

Claims (7)

1. A method of using colchicine for prophylactic treatment of gout flares in an adult human gout patient so as to reduce the occurrence of colchicine toxicity when said patient is receiving concomitant administration of clarithromycin, said method comprising:

orally administering a reduced colchicine daily dosage amount to the patient for prophylactic treatment of gout flares, wherein the reduced colchicine daily dosage amount is a 75% reduction of a colchicine dosage amount adapted for oral administration to the gout patient for the prophylaxis of gout flares in the absence of concomitant administration of clarithromycin,

wherein concomitant administration of clarithromycin is administration within 1 to 2 days of orally administering the second colchicine dosage amount.

2. The method of claim 1 , wherein the colchicine dosage amount adapted for oral administration to the gout patient for the prophylaxis of gout flares in the absence of concomitant administration of clarithromycin is 0.6 mg twice per day.

3. The method of claim 2 , wherein the reduced colchicine dosage amount is 0.3 mg once per day.

4. The method of claim 1 , wherein the colchicine dosage amount adapted for oral administration to the gout patient for the prophylaxis of gout flares in the absence of concomitant administration of clarithromycin is 0.6 mg once per day.

5. The method of claim 4 , wherein the reduced colchicine dosage amount is 0.3 mg once every other day.

Assignments (4)
MERGER Recorded Nov 30, 2012
From: AR HOLDING COMPANY, INC.
To: MPC OLDCO, INC.
Reel/Frame 029378/0850 →
MERGER Recorded Nov 30, 2012
From: MPC OLDCO, INC.
To: MPC MERGER SUB, INC.
Reel/Frame 029380/0671 →
MERGER Recorded Nov 30, 2012
From: MPC MERGER SUB, INC.
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 029380/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2012
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: AR HOLDING COMPANY, INC.
Reel/Frame 027492/0011 →